Date: 2016-09-25
Type of information: Collaboration agreement
Compound: diagnostic and therapeutic solutions for the treatment of cancer
Company: Philips (The Netherlands) IBA (Belgium)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: collaboration
Action mechanism:
Disease: cancer
Details: * On September 11, 2014, IBA (Ion Beam Applications S.A.), a leading provider of proton therapy and radiopharmacy solutions, and Royal Philips announced the signing of a global collaboration to provide advanced diagnostic and therapeutic solutions for the treatment of cancer. The commercial collaboration also includes an integrated offering for Molecular Imaging Centers, combining IBA’s expertise in PET radioisotope production centers with Philips imaging and diagnostics expertise.
The collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. By merging their respective expertise in therapy and image guidance systems, IBA and Philips will innovate with an integrated vision for more efficient, personalized cancer care. The collaboration will also enable both organizations to mutually leverage technologies and solutions: IBA will benefit from Philips diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world.
Financial terms:
Latest news: * On September 25, 2016, IBA and Philips announced that building on their collaborative achievements since 2014 to provide advanced diagnostic and therapeutic oncology solutions, the two companies are stepping up their combined efforts in adaptive proton therapy planning. The long-term collaboration between the two companies includes the joint marketing and sales of Philips’ imaging and clinical informatics solutions in oncology and IBA’s proton therapy solutions and the joint development of new products for image-guided proton therapy and treatment modalities. By merging their respective expertise in image guidance and therapy, Philips and IBA continue to co-innovate in diagnostic and therapeutic oncology solutions with the ultimate objective of enabling more effective and personalized cancer care. IBA and Philips share the understanding that adaptive therapy planning is key to meeting this objective. The strategic partners have already secured certified compatibility between Philips’ Pinnacle3 therapy planning software and IBA’s proton therapy solution, and they will now jointly develop next-generation proton therapy planning methods to further increase efficiencies in the patient treatment workflow. Also a result of the collaboration, more than 30 IBA proton therapy centers are expected to benefit from an enhanced Cone Beam CT imaging technology. This advanced imaging technology provides the large field-of-view needed for enhanced image guidance during proton therapy procedures. To this end, a new software algorithm with an optimized balance between speed and image quality has been developed by the two long-term partners. IBA and Philips offer unique integrated solutions for proton therapy and molecular imaging centers. They are currently installing state-of-the-art proton therapy solutions at three compact proton therapy centers in the UK, one compact center in the Middle East, and one large proton therapy center in India. Depending on the proton therapy center, the installed solution can include IBA’s proton therapy systems, such as the Proteus®ONE* and Proteus®PLUS*, and Philips’ imaging and clinical informatics solutions, such as Philips’ Big Bore CT and PET CT systems and Philips’ Pinnacle3 Treatment Planning System.
